Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium breve strain yakult + galacto-oligosaccharide
- Development stage
- Unknown
- Lead developer
- Yakult Honsha
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve strain Yakult + galacto-oligosaccharide is a synbiotic combination consisting of a specific probiotic bacterial strain and a prebiotic carbohydrate. Developed by Yakult, the therapy is designed to improve gut health by modulating the intestinal microbiota, increasing the population of beneficial bifidobacteria, and reducing the levels of potentially harmful bacteria such as Bacteroidaceae. In clinical studies for mild to moderate ulcerative colitis, the administration of this synbiotic has been shown to improve clinical status, reduce fecal pH, and decrease inflammatory markers like myeloperoxidase. It is also investigated for its potential to improve skin conditions by reducing systemic phenol levels produced by gut bacteria.
- Other names
- Bifidobacterium breve strain Yakult + GOSB. breve strain Yakult + galacto-oligosaccharidesynbiotic combination of B. breve strain Yakult and galacto-oligosaccharides
Beyond the preview
Go deeper on bifidobacterium breve strain yakult + galacto-oligosaccharide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium breve strain yakult + galacto-oligosaccharide.